CY1118763T1 - Αντισωμα αντι-ερηα2 - Google Patents

Αντισωμα αντι-ερηα2

Info

Publication number
CY1118763T1
CY1118763T1 CY20171100336T CY171100336T CY1118763T1 CY 1118763 T1 CY1118763 T1 CY 1118763T1 CY 20171100336 T CY20171100336 T CY 20171100336T CY 171100336 T CY171100336 T CY 171100336T CY 1118763 T1 CY1118763 T1 CY 1118763T1
Authority
CY
Cyprus
Prior art keywords
hybridoma
antibody
antibody produced
hera2
ferm
Prior art date
Application number
CY20171100336T
Other languages
English (en)
Inventor
designation of the inventor has not yet been filed The
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of CY1118763T1 publication Critical patent/CY1118763T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Αποκαλύπτονται: αντίσωμα δυνάμενο αναστολής της καρκινοποίησης κυττάρου και/ή της υπερπλασίας κυττάρου όγκου• και άλλων. Συγκεκριμένα αποκαλύπτονται: αντίσωμα το οποίο μπορεί να αναγνωρίσει έναν επίτοπο που μπορεί να αναγνωριστεί από αντίσωμα που παράγεται από υβριδίωμα SH 348-1 (FERM BP-10836) ή υβριδίωμα SH 357-1 (FERM ΒΡ-10837)• αντίσωμα που παράγεται από υβριδίωμα SH 348-1 ή υβριδίωμα SH 357-1• αντίσωμα το οποίο παράγεται από ανθρωποποίηση αντισώματος που παράγεται από υβριδίωμα SH 348-1 ή υβριδίωμα SH 357-1• φαρμακευτικός παράγων που περιλαμβάνει το οποιοδήποτε ένα από τα προαναφερθέντα αντισώματα ως ένα ενεργό συστατικό μίγματος• και άλλα.
CY20171100336T 2007-08-30 2017-03-16 Αντισωμα αντι-ερηα2 CY1118763T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007224007 2007-08-30
PCT/JP2008/065486 WO2009028639A1 (ja) 2007-08-30 2008-08-29 抗ｅｐｈａ２抗体

Publications (1)

Publication Number Publication Date
CY1118763T1 true CY1118763T1 (el) 2017-07-12

Family

ID=40387351

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100336T CY1118763T1 (el) 2007-08-30 2017-03-16 Αντισωμα αντι-ερηα2

Country Status (26)

Country Link
US (3) US8449882B2 (el)
EP (1) EP2199390B1 (el)
JP (2) JP5312333B2 (el)
KR (4) KR101561403B1 (el)
CN (1) CN101848998B (el)
AU (1) AU2008292352B2 (el)
BR (1) BRPI0816094A2 (el)
CA (1) CA2698146C (el)
CO (1) CO6180469A2 (el)
CY (1) CY1118763T1 (el)
DK (1) DK2199390T3 (el)
ES (1) ES2618316T3 (el)
HR (1) HRP20170407T1 (el)
HU (1) HUE032301T2 (el)
IL (1) IL204211A (el)
LT (1) LT2199390T (el)
MX (1) MX2010002248A (el)
MY (1) MY150621A (el)
NZ (1) NZ583966A (el)
PL (1) PL2199390T3 (el)
PT (1) PT2199390T (el)
RU (1) RU2525133C2 (el)
SI (1) SI2199390T1 (el)
TW (1) TWI443109B (el)
WO (1) WO2009028639A1 (el)
ZA (1) ZA201001340B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2012008397A1 (ja) * 2010-07-12 2012-01-19 第一三共株式会社 抗ｅｐｈａ２抗体及びその用途
WO2012012759A2 (en) * 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN109069602B (zh) * 2016-04-14 2022-11-22 刘扶东 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
CA3026490A1 (en) * 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
CN110198956A (zh) * 2017-01-23 2019-09-03 学校法人东洋大学 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测
US11421032B2 (en) * 2017-05-22 2022-08-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of MICA/B shedding
CN109879965B (zh) * 2017-12-06 2022-11-11 北京科立思维生物科技有限公司 抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用
MX2021002107A (es) 2018-09-06 2021-04-28 Daiichi Sankyo Co Ltd Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo.
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
US20220306752A1 (en) * 2021-03-05 2022-09-29 Atreca, Inc. Epha2 antibodies
WO2022191313A1 (ja) 2021-03-12 2022-09-15 第一三共株式会社 糖鎖及び糖鎖を含む医薬品の製造方法
EP4349857A1 (en) 2021-05-25 2024-04-10 Vaxcell-Bio Monobody-based chimeric antigen receptor and immune cell including same

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
EP2312316A1 (en) 1999-08-17 2011-04-20 Purdue Research Foundation Anti-EPHA2 antibodies as a cancer diagnostic
ES2261230T3 (es) * 1999-08-17 2006-11-16 Purdue Research Foundation Tratamiento de la enfermedad metastasica.
MXPA02009454A (es) 2000-03-31 2003-04-10 Purdue Research Foundation Metodo de tratamiento usando conjugados ligando-inmunogeno.
WO2002000728A2 (en) 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies
US7101976B1 (en) * 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6931956B2 (en) * 2001-06-05 2005-08-23 Valeo Locking device with transmission gears
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003004057A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
CA2485548A1 (en) 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
AU2003243228B2 (en) * 2002-05-10 2009-03-26 Medimmune, Llc EphA2 monoclonal antibodies and methods of use thereof
EP1505999A4 (en) 2002-05-23 2009-07-08 Purdue Research Foundation LOW WEIGHT MOLECULAR WEIGHT TYROSINE PHOSPHATASE (LMW-PTP) AS A TARGET FOR DIAGNOSTIC AND THERAPEUTIC USE
US7326552B1 (en) * 2002-06-21 2008-02-05 Takeda San Diego, Inc. Wild-type kinase domain of human Ephrin receptor A2 (EPHA2) and crystallization thereof
EP1852441B1 (en) 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1553963A4 (en) 2002-09-24 2006-05-03 Burnham Inst NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
AU2004229543A1 (en) 2003-04-11 2004-10-28 Medimmune, Llc EphA2 and non-neoplastic hyperproliferative cell disorders
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
EP1618184A4 (en) 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
WO2004101764A2 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en) 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
US20050009033A1 (en) 2003-07-08 2005-01-13 The Regents Of The University Of California Breast cancer genes
WO2005016381A2 (en) 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
US20050048550A1 (en) 2003-07-30 2005-03-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education EphA2 T-cell epitope agonists and uses therefor
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
AU2004281834A1 (en) 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
DE10354115A1 (de) * 2003-11-19 2005-07-21 Beiersdorf Ag Neue Verwendung von Tensidsystemen zur Verringerung der Schädigung hauteigener Enzyme
KR20060135671A (ko) * 2003-11-20 2006-12-29 메디뮨 인코포레이티드 ＥｐｈＡ２ 작동성 모노클로날 항체 및 이의 사용 방법
WO2005056766A2 (en) 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
WO2005067460A2 (en) 2003-12-24 2005-07-28 Medimmune, Inc. Epha2 vaccines
US20060286102A1 (en) 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
JP2008510008A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
US8222253B2 (en) 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2006047638A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585671A1 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
ZA200707275B (en) 2005-02-04 2009-01-28 Raven Biotechnologies Inc Antibodies that bind to EphA2 and methods of use thereof
EP1858911A4 (en) 2005-03-14 2009-12-16 Medimmune Inc MACROMOLECULES WITH THIOETER NETWORKING
WO2007018671A2 (en) 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2009506790A (ja) * 2005-09-07 2009-02-19 メディミューン，エルエルシー 毒素とコンジュゲートしたｅｐｈ受容体抗体
WO2007035451A2 (en) 2005-09-16 2007-03-29 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
WO2007075706A2 (en) * 2005-12-21 2007-07-05 Medimmune, Inc. Affinity optimized epha2 agonistic antibodies and methods of use thereof
AU2006327175A1 (en) 2005-12-21 2007-06-28 Medimmune, Llc Epha2 bite molecules and uses thereof
JP2009525048A (ja) 2006-02-01 2009-07-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体
US20080003210A1 (en) * 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
US20100093626A1 (en) 2006-12-15 2010-04-15 Bingcheng Wang Peptide and small molecule agonists of epha and their uses in disease
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US20100210708A1 (en) 2007-04-13 2010-08-19 Cytopathfinder, Inc. Compound profiling method
CA2690449A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
US20120039870A9 (en) 2007-09-07 2012-02-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies

Also Published As

Publication number Publication date
HRP20170407T1 (hr) 2017-05-05
EP2199390B1 (en) 2016-12-21
PT2199390T (pt) 2017-03-15
KR101561417B1 (ko) 2015-10-16
KR20150008931A (ko) 2015-01-23
MX2010002248A (es) 2010-03-25
US8449882B2 (en) 2013-05-28
IL204211A (en) 2016-04-21
NZ583966A (en) 2012-04-27
CO6180469A2 (es) 2010-07-19
CN101848998A (zh) 2010-09-29
RU2525133C2 (ru) 2014-08-10
US9150657B2 (en) 2015-10-06
PL2199390T3 (pl) 2017-06-30
KR101561403B1 (ko) 2015-10-16
JPWO2009028639A1 (ja) 2010-12-02
KR101561416B1 (ko) 2015-10-16
KR20100057018A (ko) 2010-05-28
US20160031987A1 (en) 2016-02-04
SI2199390T1 (sl) 2017-02-28
US20100183618A1 (en) 2010-07-22
AU2008292352B2 (en) 2012-03-08
ES2618316T3 (es) 2017-06-21
KR101521668B1 (ko) 2015-05-28
US20140212439A1 (en) 2014-07-31
JP5688433B2 (ja) 2015-03-25
BRPI0816094A2 (pt) 2015-03-03
MY150621A (en) 2014-02-14
RU2010111896A (ru) 2011-10-10
KR20150041811A (ko) 2015-04-17
CA2698146A1 (en) 2009-03-05
EP2199390A4 (en) 2012-12-12
HUE032301T2 (en) 2017-09-28
CN101848998B (zh) 2016-08-03
DK2199390T3 (en) 2017-04-03
WO2009028639A1 (ja) 2009-03-05
KR20150041186A (ko) 2015-04-15
AU2008292352A1 (en) 2009-03-05
JP2013198492A (ja) 2013-10-03
TW200916480A (en) 2009-04-16
EP2199390A1 (en) 2010-06-23
JP5312333B2 (ja) 2013-10-09
ZA201001340B (en) 2010-11-24
TWI443109B (zh) 2014-07-01
CA2698146C (en) 2016-12-20
LT2199390T (lt) 2017-03-10

Similar Documents

Publication Publication Date Title
CY1118763T1 (el) Αντισωμα αντι-ερηα2
CY1123577T1 (el) Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CY1124965T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
IL244803A0 (en) Human anti-beta7 antibodies and their use
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
PE20140833A1 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
TW200745161A (en) Stable antibody formulation
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
TW200744632A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA200970923A1 (ru) АНТИ-EpСАМ АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
MX2009006034A (es) Anticuerpos antagonistas contra ephb3.
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
CY1119315T1 (el) Στερεες μορφες που περιεχουν μελοξικαμη με βελτιωμενη στοματικη γευση και η διαδικασια για τηn προετοιμασια τους
CY1116949T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου